We have discovered that the very presence of mutations is not needed to drive cancer development.
Instead, metabolic abnormalities are driven directly by an unnoticed mechanism that does not cause mutations by itself.
Cancer Research and Biotechnology AG (CRB) is a Swiss preclinical biopharma company focusing on mitochondrial healing. CRB develops small molecule -based drugs to reverse the tumorigenic mitochondrial dysfunctions that cause cancer.
INNOVATION BASED ON THE
DISCOVERY OF THE ROOT
CAUSE OF CANCER
REVERSE
CARCINOGENESIS
The mechanism amplifies the carcinogenic effect of known carcinogens by 30 times.
Therefore, while most causes for cancer are well known, there is a trigger that initiates and enables carcinogenesis.
We have invented a feasible way to reverse this sudden acceleration of carcinogenesis.
CANCER KILLS
There are many fatal and untreatable cancers.
Overall, although there has been advancement in the way of prolonged survival, cancer kill rate has not improved since 1950’s. The tumors will return because the tumor-causing disease remains.
So far, all cancer treatments aim to kill cancer cells.
Many tumors become resistant to the novel chemotherapies.
While initially promising, the new genetic and immunological treatments can help only a few patients.
STRATEGY
RESEARCH AND INNOVATION
Based on its innovation, Cancer Research and Biotechnology AG has developed a proprietary new therapeutic entity to treat cancer’s root causes and to reverse carcinogenesis. CRB has invented and patented a method to treat the disease that can lead to tumors.
The first use, or indications, will be against the most fatal and hard to treat cancers. These are also the most ethical targets, and as such, they will open the fastest regulatory pathways to first human use.
